[SCHEDULE 13D/A] Adaptimmune Therapeutics plc American SEC Filing

Rhea-AI Filing Summary

This Amendment No. 3 to the Schedule 13D updates prior filings by New Enterprise Associates-related reporting persons concerning Adaptimmune Therapeutics Plc ordinary shares. Collectively the reporting persons hold 4 Ordinary Shares (the "Firm Shares"), which the filing states represents 0% of the class based on 1,590,309,546 Ordinary Shares outstanding. The filing discloses shared voting and dispositive power over those 4 shares and identifies the funds, control entities and individual managers involved. The Amendment attaches Schedule A for recent transactions and cites Exhibit 1 (joint filing agreement) and Exhibit 3 (power of attorney).

Positive

• Transparent disclosure of ownership structure and recent transactions via Amendment No. 3 and attached Schedule A
• Procedural compliance with SEC reporting: joint filing agreement and power of attorney exhibits are provided

Negative

• De minimis ownership: only 4 Ordinary Shares reported, representing 0% of the outstanding class
• No material influence on control or voting given the negligible stake

Insights

Financial Analyst

TL;DR: NEA entities report a de minimis combined holding of 4 shares in ADAP, representing 0% of outstanding stock; no material ownership change.

The filing documents that New Enterprise Associates funds and affiliated control entities collectively hold 4 Ordinary Shares of Adaptimmune, with shared voting and dispositive power reported as 4 shares. The ownership percentage is calculated against 1,590,309,546 shares outstanding as reported by the issuer. The Amendment references prior Schedule 13D filings and attaches a Schedule A of recent transactions. From an investor-impact standpoint, the position disclosed is immaterial to company control, capital structure, or voting outcomes.

Corporate Governance Expert

TL;DR: Amendment updates ownership and organizational relationships; disclosed stake is nominal and unlikely to affect governance.

The filing clarifies the chain of control among NEA 14, NEA 16, their GP entities and named managers, and confirms that each Reporting Person disclaims beneficial ownership except as recorded. It documents delegated approval rights on dispositions via an Executive Committee member. The documentation of exhibits (joint filing agreement, transaction schedule, power of attorney) reflects procedural compliance with reporting rules but does not indicate any governance influence given the 4-share holding.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)

Adaptimmune Therapeutics Plc

(Name of Issuer)

Ordinary Shares, (pound).001 par value per share

(Title of Class of Securities)

00653A107

(CUSIP Number)

Stephanie Brecher
New Enterprise Associates, 1954 Greenspring Drive, Suite 600
Timonium, MD, 21093
(410) 842-4000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/15/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 00653A107

1

Name of reporting person

New Enterprise Associates 14, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 4.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 4.00

11

Aggregate amount beneficially owned by each reporting person

4.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP No. 00653A107

1

Name of reporting person

NEA Partners 14, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 4.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 4.00

11

Aggregate amount beneficially owned by each reporting person

4.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP No. 00653A107

1

Name of reporting person

NEA 14 GP, LTD

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 4.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 4.00

11

Aggregate amount beneficially owned by each reporting person

4.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

CUSIP No. 00653A107

1

Name of reporting person

New Enterprise Associates 16, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 4.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 4.00

11

Aggregate amount beneficially owned by each reporting person

4.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP No. 00653A107

1

Name of reporting person

NEA Partners 16, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 4.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 4.00

11

Aggregate amount beneficially owned by each reporting person

4.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP No. 00653A107

1

Name of reporting person

NEA 16 GP, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 4.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 4.00

11

Aggregate amount beneficially owned by each reporting person

4.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP No. 00653A107

1

Name of reporting person

Forest Baskett

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 4.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 4.00

11

Aggregate amount beneficially owned by each reporting person

4.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP No. 00653A107

1

Name of reporting person

Anthony A. Florence, Jr.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 4.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 4.00

11

Aggregate amount beneficially owned by each reporting person

4.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP No. 00653A107

1

Name of reporting person

Patrick J. Kerins

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 4.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 4.00

11

Aggregate amount beneficially owned by each reporting person

4.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP No. 00653A107

1

Name of reporting person

Mohamad H. Makhzoumi

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 4.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 4.00

11

Aggregate amount beneficially owned by each reporting person

4.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP No. 00653A107

1

Name of reporting person

Scott D. Sandell

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 4.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 4.00

11

Aggregate amount beneficially owned by each reporting person

4.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Ordinary Shares, (pound).001 par value per share
(b)	Name of Issuer: Adaptimmune Therapeutics Plc
(c)	Address of Issuer's Principal Executive Offices: 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, UNITED KINGDOM , OX14 4RX.
Item 1 Comment: This Amendment No. 3 ("Amendment No. 3") to Schedule 13D amends the Schedule 13D originally filed on September 17, 2018 (the "Schedule 13D"), Amendment No. 1 thereto filed on March 30, 2023 ("Amendment No. 1") and Amendment No. 2 thereto filed on April 2, 2024 ("Amendment No. 2"), and relates to the ordinary shares, (pound).001 par value (the "Ordinary Shares"), including Ordinary Shares represented by American Depositary Shares (the "ADS"), with each ADS representing six Ordinary Shares, of the Issuer. Certain terms used but not defined in this Amendment No. 3 have the meanings assigned thereto in the Schedule 13D (including Amendment No. 1 and Amendment No. 2 thereto). Except as specifically provided herein, this Amendment No. 3 does not modify any of the information previously reported on the Schedule 13D (including Amendment No. 1 and Amendment No. 2 thereto).
Item 2.	Identity and Background
(a)	New Enterprise Associates 14, L.P. ("NEA 14") and New Enterprise Associates 16, L.P. ("NEA 16" and collectively with NEA 14, the "Funds"); NEA Partners 14, L.P. ("NEA Partners 14"), which is the sole general partner of NEA 14, and NEA Partners 16, L.P. ("NEA Partners 16" and collectively with NEA Partners 14, the "GPLPs"), which is the sole general partner of NEA 16; NEA 14 GP, LTD ("NEA 14 GP"), which is the sole general partner of NEA Partners 14, and NEA 16 GP, LLC ("NEA 16 GP" and, collectively with the GPLPs and NEA 14 GP, the "Control Entities"), which is the sole general partner of NEA Partners 16; and Forest Baskett ("Baskett"), Anthony A. Florence, Jr. ("Florence"), Patrick J. Kerins ("Kerins"), Mohamad H. Makhzoumi ("Makhzoumi") and Scott D. Sandell ("Sandell") (together, the "Managers"). Baskett, Florence, and Sandell (the "Dual Managers") are directors of NEA 14 GP and managers of NEA 16 GP. Kerins is a director of NEA 14 GP (the "NEA 14 Director"). Florence, Makhzoumi, and Sandell are also members of the Executive Committee of NEA Management Company, LLC (the "Executive Committee"). The persons named in this Item 2 are referred to individually herein as a "Reporting Person" and collectively as the "Reporting Persons."
(b)	The address of the principal business office of the Funds, each Control Entity, Kerins and Sandell is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. The address of the principal business office of Baskett and Makhzoumi is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, CA 94025. The address of the principal business office of Florence is New Enterprise Associates, 104 5th Avenue, 19th Floor, New York, NY 10011.
(c)	The principal business of each Fund is to invest in and assist growth-oriented businesses located principally in the United States. The principal business of NEA Partners 14 is to act as the sole general partner of NEA 14. The principal business of NEA Partners 16 is to act as the sole general partner of NEA 16. The principal business of NEA 14 GP is to act as the sole general partner of NEA Partners 14. The principal business of NEA 16 GP is to act as the sole general partner of NEA Partners 16. The principal business of each of the Managers and the Executive Committee is to manage the Control Entities, the Funds and a number of affiliated partnerships with similar businesses.
(d)	During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(e)	During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f)	Each of NEA 14 and NEA Partners 14 is a Cayman Islands exempted limited partnership. NEA 14 GP is a Cayman Islands exempted company. Each of NEA 16 and NEA Partners 16 is a Delaware limited partnership. NEA 16 GP is a limited liability company organized under the laws of the State of Delaware. Each of the Managers is a United States citizen.
Item 3.	Source and Amount of Funds or Other Consideration
	Not applicable.
Item 4.	Purpose of Transaction
	Schedule A attached hereto as Exhibit 2 describes all transactions in the Issuer's Ordinary Shares that were effected by the Reporting Persons during the past 60 days. Depending on market conditions and other factors, the Funds and other Reporting Persons may dispose of additional shares of the Issuer.
Item 5.	Interest in Securities of the Issuer
(a)	As of August 18, 2025, NEA 14 is the record owner of 4 Ordinary Shares (the "NEA 14 Shares"). As the general partner of NEA 14, NEA Partners 14 may be deemed to own beneficially the NEA 14 Shares. As the sole general partner of NEA Partners 14, NEA 14 GP may be deemed to own beneficially the NEA 14 Shares. As directors of NEA 14 GP each of the Dual Managers and the NEA 14 Director may be deemed to own beneficially the NEA 14 Shares. As an individual member of the Executive Committee, which committee has been delegated certain approval rights with respect to dispositions of the NEA 14 Shares, Makhzoumi may also be deemed to own beneficially the NEA 14 Shares. As of August 18, 2025, NEA 16 is the record owner of 0 Ordinary Shares. Collectively, the Funds now hold a total of 4 Ordinary Shares (the "Firm Shares"). By virtue of their relationship as affiliated entities, whose controlling entities have substantially overlapping individual controlling persons, each of the Funds and the Control Entities may be deemed to share the power to direct the disposition and vote of the Firm Shares. Each Reporting Person disclaims beneficial ownership of the Firm Shares other than those shares which such person owns of record. The percentage of outstanding Ordinary Shares of the Issuer which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person's cover sheet. Such percentage was calculated for each Reporting Person based on the 1,590,309,546 Ordinary Shares reported by the Issuer to be outstanding as of August 11, 2025, on the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 13, 2025.
(b)	Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets (ii) shared power to vote or to direct the vote: See line 8 of cover sheets (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets.
(c)	Schedule A attached hereto as Exhibit 2 describes all transactions in the Issuer's Ordinary Shares that were effected by the Reporting Persons during the past 60 days.
(d)	No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, Ordinary Shares beneficially owned by any of the Reporting Persons.
(e)	August 15, 2025.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Not applicable.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 1 - Agreement regarding filing of joint Schedule 13D. Exhibit 2 - Schedule A: Transactions during the past 60 days. Exhibit 3 - Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

New Enterprise Associates 14, L.P.

Signature:	/s/ Zachary Bambach
Name/Title:	Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:	08/19/2025

Signature:	/s/ Zachary Bambach
Name/Title:	Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:	08/19/2025

NEA Partners 14, L.P.

Signature:	/s/ Zachary Bambach
Name/Title:	Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:	08/19/2025

Signature:	/s/ Zachary Bambach
Name/Title:	Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:	08/19/2025

NEA 14 GP, LTD

Signature:	/s/ Zachary Bambach
Name/Title:	Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:	08/19/2025

Signature:	/s/ Zachary Bambach
Name/Title:	Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:	08/19/2025

New Enterprise Associates 16, L.P.

Signature:	/s/ Zachary Bambach
Name/Title:	Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:	08/19/2025

Signature:	/s/ Zachary Bambach
Name/Title:	Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:	08/19/2025

NEA Partners 16, L.P.

Signature:	/s/ Zachary Bambach
Name/Title:	Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:	08/19/2025

Signature:	/s/ Zachary Bambach
Name/Title:	Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:	08/19/2025

NEA 16 GP, LLC

Signature:	/s/ Zachary Bambach
Name/Title:	Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
Date:	08/19/2025

Signature:	/s/ Zachary Bambach
Name/Title:	Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
Date:	08/19/2025

Forest Baskett

Signature:	/s/ Zachary Bambach
Name/Title:	Zachary Bambach as attorney-in-fact for Forest Baskett
Date:	08/19/2025

Anthony A. Florence, Jr.

Signature:	/s/ Zachary Bambach
Name/Title:	Zachary Bambach as attorney-in-fact for Anthony A. Florence, Jr.
Date:	08/19/2025

Patrick J. Kerins

Signature:	/s/ Zachary Bambach
Name/Title:	Zachary Bambach as attorney-in-fact for Patrick J. Kerins
Date:	08/19/2025

Mohamad H. Makhzoumi

Signature:	/s/ Zachary Bambach
Name/Title:	Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi
Date:	08/19/2025

Scott D. Sandell

Signature:	/s/ Zachary Bambach
Name/Title:	Zachary Bambach as attorney-in-fact for Scott D.Sandell
Date:	08/19/2025

Comments accompanying signature:

This Amendment No. 3 to Schedule 13D was executed by Zachary Bambach on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached as Exhibit 3.

FAQ

How many Adaptimmune (ADAP) shares do the New Enterprise Associates reporting persons hold?

They collectively hold 4 Ordinary Shares of Adaptimmune, described in the filing as the "Firm Shares."

What percentage of ADAP outstanding shares does the filing report?

The filing calculates the position as 0% based on 1,590,309,546 Ordinary Shares outstanding reported by the issuer.

Do the NEA reporting persons have voting or dispositive power over the shares?

Yes; the cover sheets report shared voting power 4 and shared dispositive power 4 for the reporting persons.

Does the Amendment include details of recent transactions in ADAP shares?

Yes; the filing states that Schedule A (Exhibit 2) describes all transactions in the past 60 days.

What exhibits are attached to this Amendment No. 3?

The filing lists Exhibit 1 (joint filing agreement), Exhibit 2 (Schedule A: recent transactions) and Exhibit 3 (power of attorney).